Introduction
Creatine Kinase (CK) exists as three isoenzymes (MM, MB, and BB) distributed in muscle, cardiac, and brain tissues. These recombinant CK proteins serve as valuable tools for calibrating diagnostic instruments and supporting research on neuromuscular diseases. Their applications span a range of neuromuscular disorders, including cardiac diseases, mitochondrial disorders, inflammatory myopathies, myasthenia gravis, polymyositis, McArdle's disease, neuromuscular junction disorders, muscular dystrophy, amyotrophic lateral sclerosis (ALS), thyroid disorders, central core disease, acid maltase deficiency, myoglobinuria, rhabdomyolysis, motor neuron diseases, rheumatic diseases, and other conditions characterized by abnormal creatine kinase levels.
Description
CKMT3 Human Recombinant is a glycosylated polypeptide chain produced in Pichia Pastoris. This recombinant protein exhibits an identical amino acid sequence to the native CKMT3 enzyme. Purified under non-denaturing conditions, it demonstrates reactivity with polyclonal antibodies specific to the MM isoenzyme in ELISA assays. The purification process for CKMT3 involves proprietary chromatographic techniques.
Physical Appearance
Sterile Filtered colorless liquid.
Formulation
The protein formulation contains 20mM Tris pH 8.0, 1mM EDTA, and 1mM DTT for each mg of protein.
Stability
While CKMT3 remains stable at 15°C for up to 7 days, storage below -18°C is recommended. Repeated freeze-thaw cycles should be avoided.
Purity
The purity is greater than 95.0% as determined by: (a) Reverse-phase high-performance liquid chromatography (RP-HPLC) analysis and (b) Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Biological Activity
The biological activity, assessed using the Creatine Phosphokinase assay procedure No. 45-UV (1 IU = 1 µmole creatine phosphate), was determined to be 500 IU/mg at 37°C. This corresponds to a specific activity of 2,000 ng/ml.
Synonyms
Creatine kinase M-type, EC 2.7.3.2, Creatine kinase M chain, M-CK, CKM, CKMM, CKMMITIII.